SequelSEC

International Stem Cell CORP ISCO

Pharmaceutical Preparations · CIK 0001355790 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.68M
Fiscal year ended 2026-06-30
Operating income
-$35.00K
Fiscal year ended 2026-06-30
Free cash flow
$160.00K
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$592.08KMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.07Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue7.5%11th
Current ratio0.74x12th
SBC / revenue3.2%15th
Operating margin-2.9%78th
Net margin-4.6%73th
CapEx / revenue0.5%29th
FCF margin-0.4%71th
Gross margin55.7%33th
Revenue YoY growth0.2%46th

International Stem Cell CORP (ISCO) reported revenue of $2.68M and net income of -$71.00K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from International Stem Cell CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

International Stem Cell CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$2.68M$2.32M$2.16M$2.37M$2.45M$2.13M$2.45M$2.18M$2.33M$2.13M
Cost of revenue$1.22M$954.00K$1.07M$1.05M$927.00K$992.00K$990.00K$974.00K$913.00K$887.00K
Gross profit$1.46M$1.36M$1.09M$1.32M$1.52M$1.14M$1.46M$1.20M$1.42M$1.24M
Operating income-$35.00K-$190.00K-$313.00K$94.00K$167.00K-$215.00K$51.00K-$90.00K$149.00K-$178.00K
Net income-$71.00K-$220.00K-$348.00K$57.00K$129.00K-$256.00K$11.00K-$125.00K$119.00K-$214.00K
Research & development$155.00K$156.00K$177.00K$158.00K$162.00K$187.00K$210.00K$187.00K$83.00K$177.00K
Weighted-average diluted sharesshares 8.00Mshares 8.00MUnavailableshares 8.17Mshares 8.00Mshares 8.00MUnavailableshares 8.00Mshares 8.00Mshares 8.00M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.01$-0.03Unavailable$0.00$0.01$-0.03Unavailable$-0.02$0.01$-0.03
Selling, general & administrative$1.34M$1.40M$1.22M$1.07M$1.19M$1.16M$1.20M$1.11M$1.19M$1.24M
General & administrative$1.06M$1.12M$946.00K$789.00K$905.00K$892.00K$907.00K$816.00K$884.00K$909.00K
Selling & marketing$276.00K$273.00K$279.00K$280.00K$286.00K$273.00K$288.00K$292.00K$302.00K$334.00K

Balance

International Stem Cell CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$5.06M$5.13M$4.82M$5.28M$5.55M$5.62M$5.17M$5.18M$5.59M$5.37M
Current assets$3.92M$3.81M$3.41M$3.73M$3.84M$3.84M$3.56M$3.49M$3.82M$3.59M
Total liabilities$4.98M$5.05M$4.58M$4.76M$5.14M$5.41M$4.80M$4.92M$5.31M$5.33M
Current liabilities$4.98M$5.05M$4.58M$4.66M$4.94M$5.11M$4.69M$4.72M$5.02M$4.97M
Total equity incl. NCI-$4.23M-$4.22M-$4.06M-$3.78M-$3.90M-$4.09M-$3.93M-$4.04M-$4.02M-$4.26M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.68M$1.77M$1.51M$1.59M$1.55M$1.26M$1.15M$1.38M$1.42M$1.27M
Accounts receivable$959.00K$791.00K$723.00K$1.02M$1.10M$851.00K$1.06M$680.00K$810.00K$632.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$310.00K$437.00K$168.00K$265.00K$397.00K$457.00K$186.00K$321.00K$377.00K$360.00K

Cash flow

International Stem Cell CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$167.00K$121.00K$32.00K$49.00K-$300.00K$227.00K-$74.00K$257.00K$23.00K-$193.00K
Capital expenditures$7.00K$23.00K$3.00K$3.00K$32.00K$5.00K$1.00K$37.00K$120.00K$8.00K
Investing cash flow-$11.00K-$31.00K-$5.00K-$3.00K-$32.00K-$5.00K-$3.00K-$40.00K-$119.00K-$9.00K
Financing cash flow$0-$150.00K$0$0UnavailableUnavailable$0UnavailableUnavailableUnavailable
Net change in cash$156.00K-$60.00K$27.00K$46.00K-$532.00K$222.00K-$77.00K$17.00K-$96.00K-$202.00K
Stock-based compensation$59.00K$64.00K$64.00K$63.00K$61.00K$100.00K$100.00K$100.00K$129.00K$137.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$28.00K$34.00K$34.00K$56.00K$54.00K$55.00K$54.00K$53.00K$50.00K$49.00K

Derived

International Stem Cell CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$160.00K$98.00K$29.00K$46.00K-$332.00K$222.00K-$75.00K$220.00K-$97.00K-$201.00K
Gross margin54.5%58.8%50.5%55.8%62.1%53.4%59.5%55.3%60.8%58.3%
Operating margin-1.3%-8.2%-14.5%4.0%6.8%-10.1%2.1%-4.1%6.4%-8.4%
FCF margin6.0%4.2%1.3%1.9%-13.6%10.4%-3.1%10.1%-4.2%-9.4%
SBC / revenue2.2%2.8%3.0%2.7%2.5%4.7%4.1%4.6%5.5%6.4%
Current ratio0.79x0.76x0.74x0.80x0.78x0.75x0.76x0.74x0.76x0.72x
Revenue YoY growth9.3%8.7%-11.9%8.7%5.0%0.0%29.5%10.4%26.6%2.1%
Net margin-2.7%Unavailable-16.1%2.4%5.3%Unavailable0.4%-5.7%UnavailableUnavailable
R&D / revenue5.8%6.7%8.2%6.7%6.6%8.8%8.6%8.6%3.6%8.3%
CapEx / revenue0.3%1.0%0.1%0.1%1.3%0.2%0.0%1.7%5.1%0.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ISCO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

16 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2026-06-30

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2026-03-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2025-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2025-09-30

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2025-06-30

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2025-03-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-09-30

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-06-30

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-03-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-09-30

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.